ERCC1 Antibody (8F1) - BSA Free

ERCC1, also known as RAD10, COFS4 and UV20, is a gene that functions in the nucleotide excision repair pathway. Specifically, ERCC1 is required for the repair of DNA lesions induced by UV light or formed by electrophilic compounds. ERCC1 is a heterodimer composed of ERCC1 and XPF/ERRC4 and is located in the nucleus. Mutations in ERCC1 result in cerebrooculofacio skeletal syndrome, as well as carcinogenesis. Recent research on DNA repair suggests that DNA damage may drive accelerated bone aging (PMID: 23281008), and that defaults in DNA repair mechanisms are prevalent in many lung cancers (PMID: 23276504).

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 2 confirmed species: Human, Chinese Hamster.

We have publications tested in 3 applications: IF/IHC, IHC-P, WB.

Showing Publications 1 - 10 of 16. Show All 16 Publications. Collapse Publications.

Publications using NB500-704	Applications	Species
Barone D, Iannuzzi CA, Forte IM et al. The hydrophilic extract from a new tomato genotype (named DHO) kills cancer cell lines through the modulation of the DNA damage response induced by Campthotecin treatment Frontiers in Oncology 2023-06-20 [PMID: 37409248]
Bepler G, Zinner RG, Moon J et al. A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 2014-04-18 [PMID: 24752945] (IHC-P, Human)	IHC-P	Human
Bepler G, Williams C, Schell MJ et al. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2013-07-01 [PMID: 23690416] (IHC-P, Human)	IHC-P	Human
Ozcan MF, Dizdar O, Dincer N et al. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy Urol Oncol 2012-08-02 [PMID: 22863869] (IF/IHC, Human)	IF/IHC	Human
Sodja E, Knez L, Kern I et al. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy Eur J Cancer 2012-07-11 [PMID: 22795264] (IF/IHC, Human)	IF/IHC	Human
Su CH, Chu WC, Lan KH et al. Gemcitabine causes telomere attrition by stabilizing TRF3 Eur J Cancer 2012-06-13 [PMID: 22704123] (WB, Human)	WB	Human
Soltermann A, Kilgus-Hawelski S, Behnke S et al. Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: Evaluation of antibodies 8F1 and D-10. Journal of Clinical Bioinformatics;1(1):25. 2011-09-30 [PMID: 21961533]
Besse B, Massard C, Haddad V et al. ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. Ann Oncol. 2011-03-01 [PMID: 20801905] (IF/IHC, Human)	IF/IHC	Human
Lee S, Park YH, Kim KH et al. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma. Br J Cancer. 2010-09-07 [PMID: 20700125] (IF/IHC, Human)	IF/IHC	Human
Shao YY, Kuo KT, Hu FC et al. Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin. Jpn J Clin Oncol. 2010-04-01 [PMID: 20085902] (IF/IHC, Human)	IF/IHC	Human
Bhaqwat NR, Roginskaya VY, Acquafondata MB et al. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res. 2009-09-01 [PMID: 19723666] (IF/IHC, WB, Human)	IF/IHC, WB	Human
Azim HA Jr, Pruneri g, Raviele PR et al. ERCC1 Expression in Diffuse Large B-Cell Lymphoma Patients Treated with a Cisplatin-Based Regimen : A Brief Communication. EJ Egypt Natl Canc Inst. 2007-09-01 [PMID: 19190690] (IF/IHC, Human)	IF/IHC	Human
Hwang IG, Ahn MJ, Park BB et al. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer. 2008-09-15 [PMID: 18623378] (IF/IHC, Human)	IF/IHC	Human
Jun HJ, Ahn MJ Kim HS et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer. 2008-07-08 [PMID: 18594541] (IF/IHC, Human)	IF/IHC	Human
Kim MK, Cho KJ, Kwon GY et al. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res. 2008-07-01 [PMID: 18594004] (IF/IHC, Human)	IF/IHC	Human
Al-Minawi AZ, Saleh-gohari N, Helleday T et al. The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells. Nucleic Acids Res. 2008-01-01 [PMID: 17962301] (WB, Chinese Hamster, Human)	WB	Chinese Hamster, Human
Show All 16 Publications. Collapse Publications.

Images	Ratings	Applications	Species	Date	Details
Enlarge	5 reviewed by: Verified Customer	IHC-P	Human	12/14/2011	View Summary Application Immunohistochemistry-Paraffin Sample Tested Non-small cell lung cancer Species Human

Array NB500-704

• ERCC1 Antibodies
• ERCC1 ELISA Kits
• ERCC1 Lysates
• ERCC1 Proteins